Patient characteristics
| Characteristic/category . | Treg transcriptome study . | Confirmatory analyses at gene-expression and protein level . | |
|---|---|---|---|
| Primary . | Confirmatory . | ||
| No. of patients | 6 | 20 | 72 |
| Sex, female/male | 5/1 | 13/7 | 29/43 |
| Age, y | |||
| Median (range) | 52 (26-66) | 53 (19-66) | 50 (21-72) |
| Diagnosis | |||
| AML | 3 | 10 | 31 |
| ALL | 1 | 3 | 9 |
| MDS | 2 | 7 | 26 |
| NHL | — | — | 6 |
| Donor type | |||
| MRD | 4 | 10 | 29 |
| MUD | 2 | 10 | 43 |
| Donor match | |||
| Match/mismatch | 5/1 | 18/2 | 59/12 |
| Conditioning regimen | |||
| Flu/Cy | — | — | 4 |
| Flu/Mel | — | — | 2 |
| FLAMSA-like | 3 | 12 | 29 |
| ClaraC/TBI | 1 | 3 | 13 |
| Bu/Cy | 1 | 2 | 13 |
| TBI/Cy | 1 | 3 | 11 |
| No GVHD | 3 | 8 | 25 |
| GVHD | 3 | 12 | 47 |
| Acute | 1 | 4 | 19 |
| Acute/chronic | 2 | 3 | 22 |
| Chronic | — | 5 | 6 |
| GVHD grade | |||
| Acute | |||
| I | — | 2 | 9 |
| II | — | — | 4 |
| III | 1 | 1 | 2 |
| IV | 1 | 1 | 4 |
| Chronic | |||
| Limited | — | 4 | 4 |
| Extensive | — | 1 | 2 |
| Acute/chronic | |||
| I: limited | — | 2 | 7 |
| I: extensive | — | — | 3 |
| II: limited | — | — | 4 |
| II: extensive | — | 1 | 3 |
| III: limited | — | — | 1 |
| III: extensive | 1 | — | 2 |
| IV: limited | — | — | 1 |
| IV: extensive | — | — | 1 |
| Characteristic/category . | Treg transcriptome study . | Confirmatory analyses at gene-expression and protein level . | |
|---|---|---|---|
| Primary . | Confirmatory . | ||
| No. of patients | 6 | 20 | 72 |
| Sex, female/male | 5/1 | 13/7 | 29/43 |
| Age, y | |||
| Median (range) | 52 (26-66) | 53 (19-66) | 50 (21-72) |
| Diagnosis | |||
| AML | 3 | 10 | 31 |
| ALL | 1 | 3 | 9 |
| MDS | 2 | 7 | 26 |
| NHL | — | — | 6 |
| Donor type | |||
| MRD | 4 | 10 | 29 |
| MUD | 2 | 10 | 43 |
| Donor match | |||
| Match/mismatch | 5/1 | 18/2 | 59/12 |
| Conditioning regimen | |||
| Flu/Cy | — | — | 4 |
| Flu/Mel | — | — | 2 |
| FLAMSA-like | 3 | 12 | 29 |
| ClaraC/TBI | 1 | 3 | 13 |
| Bu/Cy | 1 | 2 | 13 |
| TBI/Cy | 1 | 3 | 11 |
| No GVHD | 3 | 8 | 25 |
| GVHD | 3 | 12 | 47 |
| Acute | 1 | 4 | 19 |
| Acute/chronic | 2 | 3 | 22 |
| Chronic | — | 5 | 6 |
| GVHD grade | |||
| Acute | |||
| I | — | 2 | 9 |
| II | — | — | 4 |
| III | 1 | 1 | 2 |
| IV | 1 | 1 | 4 |
| Chronic | |||
| Limited | — | 4 | 4 |
| Extensive | — | 1 | 2 |
| Acute/chronic | |||
| I: limited | — | 2 | 7 |
| I: extensive | — | — | 3 |
| II: limited | — | — | 4 |
| II: extensive | — | 1 | 3 |
| III: limited | — | — | 1 |
| III: extensive | 1 | — | 2 |
| IV: limited | — | — | 1 |
| IV: extensive | — | — | 1 |
GVHD grade was determined according to the Glucksberg criteria.
AML indicates acute myeloid leukemia; ALL, acute lymphatic leukemia; MDS, myeloid dysplastic syndrome; NHL, non-Hodgkin lymphoma; —, not applicable; MRD, matched related donor; MUD, matched unrelated donor; Flu, fludarabine; Cy, cyclophosphamide; Mel, melphalan; FLAMSA-like, fludarabine, cyrarabine, amsacrine44 ; ClaraC, clofarabine cytarabine; TBI, total body irradiation.; and GVHD, graft-versus-host disease.